Regeneron is accused of fraudulent price reporting for eye drug

Regeneron: "Reimbursing credit card service fees to distributors is not a price concession and does not affect EYLEA's price" The DOJ last week alleged the drugmaker failed for years to report how it paid hundreds of millions of dollars to subsidize Eylea purchases.

Regeneron to defend US Justice Department's complaint on drug-pricing manipulation. U.S. Justice Department last week accused Regeneron of manipulating Medicare's drug price process by inflating the average sales price for its Eylea drug. Regeneron says it plans to defend this case in court.

U.S. Justice Department accuses Regeneron Pharmaceuticals of manipulating Medicare's drug-pricing process. Department: Drugmaker failed to report how it paid hundreds of millions of dollars to subsidize Eylea purchases. Drugmaker reimbursed drug distributors for credit-card processing fees, lawsuit says.